Responses
Immunotherapy biomarkers
Original research
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
